Comparing Lenvatinib/Pembrolizumab with Atezolizumab/Bevacizumab in Unresectable Hepatocellular Carcinoma: A Real-World Experience with Propensity Score Matching Analysis.

Cancers (Basel) · 2024 · PMC11506658 · PMID 39456553

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

showed a trendp = 0.05actually significant

Experiencing TRAEs of grade 3 or higher showed a trend towards worsening OS (HR 1.79, 95% CI 1.00–3.21, p = 0.05) and PFS (HR 1.53, 95% CI 0.90–2.59, p = 0.12).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.